ClinicalTrials.gg
TerminatedNCT00441168Updated Mar 21, 2014Results posted

Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma

A Phase 2 interventional study of adriamycin and bortezomib in Multiple Myeloma, sponsored by Janssen-Cilag International NV. Terminated at 16 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-03-21.

Sponsored by Janssen-Cilag International NV (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Why this study was terminated
TRIAL STOPPED due to a change in standard of care and the required patient numbers could no longer be achieved

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 271 studies testing bortezomib in Multiple Myeloma — 12 open to participants now, 40 under way, 14 of them phase 3. Bortezomib · Multiple Myeloma.

Enrollment
171st of 267
30 · median 41
Started
2006
with 28 others
Phase 2
137 of 271
6 open now
Registered
61st of 271
by date
Lead sponsor
5 of 271
Janssen-Cilag International NV

Among the 271 studies testing bortezomib in Multiple Myeloma, this one is the 171st largest by enrollment of the 267 interventional ones that give a count, is one of 29 that started in 2006, is one of 137 in phase 2, and was the 61st registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

12 of the 271 studies testing bortezomib in Multiple Myeloma are open now, in 10 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About bortezomib

Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 271 studies testing bortezomib in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this research study is to test the safety and effectiveness of replacing vincristine with a drug called bortezomib (also known as "Velcade"or PS341) in the standard therapy vincristine, doxorubicin (not limited to, but formerly referred to under the tradename Adriamycin) and dexamethasone (VAD) in patients with multiple myeloma. Multiple Myeloma is the second most common cancer of the blood. Bortezomib is the first approved cancer treatment in a new class of medicines called proteasome inhibitors. It disrupts the cell cycle of the cell, affecting numerous biologic pathways, including those related to growth and survival of cancer cells. The treatment will be used as second line treatment, which means either the disease has returned after a period of improvement (relapse) or the disease did not respond to the initial treatment (refractory). Patients will receive either bortezomib (PS341), doxorubicin (Adriamycin) and dexamethasone (PAD) or the VAD standard therapy.

Read the detailed description

Bortezomib, has been approved for use in patients with multiple myeloma, who have already received at least one prior treatment and whose disease is worsening on their last treatment and who have already undergone or are unsuitable for bone marrow transplantation. Bortezomib has significant activity in patients with relapsed multiple myeloma, its efficacy is increased with the addition of dexamethasone and it demonstrates synergy with doxorubicin. The VAD combination has been widely used in multiple myeloma and has demonstrated to be effective in relapsed patients. Based on previous trial results, it is hoped that bortezomib, in replacing vincristine in the VAD standard therapy, can improve the response to treatment of patients with multiple myeloma, with manageable side effects. This is an international, multicentre, randomised, open-label, parallel group study. About 212 patients will take part in the study. Patients will be treated with either bortezomib (PS-341), Adriamycin and Dexamethasone (PAD) or Vincristine, Adriamycin and Dexamethasone (VAD). There will be an initial 14 day screening period to evaluate if the patient is suitable for the study. After screening, eligible patients will be randomised to receive either PAD or VAD. Patients will receive therapy for up to 8 treatment cycles of 28 days each. After the treatment period, there will be a long-term follow-up period with monthly visits until disease progression or relapse. Thereafter follow-up will be continued by at least a phone call every other month. This long-term follow-up period will be performed for all patients until the last patient was treated and followed up for 1 year. Response to treatment will be assessed according to the European group for blood and marrow transplant criteria (EBMT). Disease burden will be monitored by measuring M-protein concentration in serum and in urine every 4 weeks until disease progression or relapse. Thereafter follow-up for survival will be continued every other month by at least a phone call. Safety will be assessed by monitoring of adverse events (AEs), vital signs, physical examination and clinical laboratory tests. Treatment with PAD or VAD will be for up to 8 cycles of 28 days each. Treatment beyond 6 cycles will be discussed on individual basis. Proposed dosages are: bortezomib 1.3 mg/m² intravenous (IV) bolus on Days 1, 4, 8, and 11; vincristine 0.4mg IV push on Days 1 to 4; doxorubicin 9mg/m² IV push on Days 1 to 4; dexamethasone in 1st cycle 40 mg daily on Days 1 to 4, 9 to 12 and 17 to 20, orally (or equivalent parenteral dose) and on subsequent cycles as 40 mg daily on Days 1 to 4 and 17 to 20 only.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • Multiple Myeloma
  • bortezomib
  • Cancer
  • Hematology
  • bone marrow
  • immunoglobulin
  • relapse
  • refractory
  • plasma cell
  • Velcade
  • adriamycin
  • dexamethasone
  • vincristine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • multiple myeloma following 1 and, is scheduled by the investigator to be treated with vincristine, adriamycin and dexamethasone standard therapy
  • measurable secretory multiple myeloma based on defined criteria
  • performance status of >or = 60%
  • fulfils defined laboratory requirements within 14 days before baseline
  • if female, the patient is either or surgically sterilised or willing to use an acceptable method of for defined period of time
  • if male, the patient agrees to use an acceptable barrier method for contraception for a defined period of time.

Exclusion criteria

Exclusion Criteria:

  • More than one for multiple myeloma
  • use of bortezomib in the previous line of therapy and/or received bortezomib in a previous trial
  • known allergy or to bortezomib, boron or mannitol
  • peripheral neuropathy or neuropathic pain of grade 2 or higher
  • myocardial infarction within 6 months of enrollment or had (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    VAD Treatment

    vincristine in combination with adriamycin and dexamethasone

    Drug: adriamycin · Drug: dexamethasone · Drug: vincristine

  • Experimental
    PAD Treatment

    bortezomib in combination with adriamycin and dexamethasone

    Drug: adriamycin · Drug: bortezomib · Drug: dexamethasone

Interventions

  • adriamycin: 9mg/m² intravenous (IV) push on days 1 to 4

  • bortezomib: 1.3 mg/m² intravenous (IV) bolus on days 1, 4, 8, and 11

  • dexamethasone: 40 mg daily days 1- 4/9-12/17-20 - cycle 1 / days 1-4/17-20 - subsequent cycle

  • vincristine: 0.4mg IV push on days 1 to 4

06

What researchers measure

Primary outcomes

  1. Best Confirmed Disease Response

    The primary efficacy analysis was based on the best response obtained during the treatment period according to the European Group for Blood and Marrow Transplantation (EBMT) criteria as assessed by the investigator. The best confirmed response was defined as 2 separate and consecutive evaluations of response, at least 6 weeks apart (for progressive disease \[PD\], 1 to 3 weeks apart). The ordering of the responses was: complete response (CR), partial response (PR), minimal response (MR), no change (NC) and PD. CR was the best response and the poorest response was PD.

    Time frame: every 28 days during treatment period for up to 6 to 8 cycles

  2. Best Reported Disease Response

    The primary efficacy analysis was based on the best response obtained during the treatment period according to the EBMT criteria as assessed by the investigator. The ordering of the responses was: CR, PR, MR, NC and PD. CR was the best response and the poorest response was PD.

    Time frame: every 28 days during treatment period for up to 6 to 8 cycles

Secondary outcomes

  1. Duration of Response (DOR)

    DOR was defined as the duration from the date of the best confirmed response for subjects who achieved CR or PR to the date of first documented evidence of PD (or relapse for subjects who experienced CR) over the duration of the study. DOR = (\[Date of PD or date of censoring - Date of best response\]+1)/30.44.

    Time frame: every 28 days during treatment period for up to 6 to 8 cycles

07

Results

Posted Mar 21, 2014
Limitations and caveats
Due to a substantial decline in the use of the VAD regimen as standard of care, recruitment of the study was halted at 30 subjects. It was not possible to statistically evaluate any long term efficacy parameter.

Participant flow

Subjects were recruited from 05 December 2006 to 04 July 2007 at 2 sites in Germany, 1 site in Hungary, 3 sites in Lithuania, 3 sites in Poland and 3 sites in Russia

Treatment Period
Participant flow — Treatment Period
MilestoneVAD TreatmentPAD Treatment
Started1713
Treated1613
Completed67
Not completed116
Withdrew: Death30
Withdrew: Adverse event12
Withdrew: Progressive disease02
Withdrew: Protocol violation01
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject30
Withdrew: Qualified for stem-cell transplantation30
Withdrew: Refractory disease10
Follow-up Period
Participant flow — Follow-up Period
MilestoneVAD TreatmentPAD Treatment
Started1713
Completed54
Not completed129
Withdrew: Death30
Withdrew: Lost to follow-up56
Withdrew: Withdrawal by subject30
Withdrew: Other13

Outcome measures

PrimaryBest Confirmed Disease Response

The primary efficacy analysis was based on the best response obtained during the treatment period according to the European Group for Blood and Marrow Transplantation (EBMT) criteria as assessed by the investigator. The best confirmed response was defined as 2 separate and consecutive evaluations of response, at least 6 weeks apart (for progressive disease \[PD\], 1 to 3 weeks apart). The ordering of the responses was: complete response (CR), partial response (PR), minimal response (MR), no change (NC) and PD. CR was the best response and the poorest response was PD.

Time frame:
every 28 days during treatment period for up to 6 to 8 cycles
Reported as:
Number · participants
Best Confirmed Disease Response
participantsVAD TreatmentPAD Treatment
CR01
PR56
Response Rate (CR + PR)57
MR20
Overall Response (CR + PR + MR)77
NC31
PD11
Unknown/Unable to Assess44
PrimaryBest Reported Disease Response

The primary efficacy analysis was based on the best response obtained during the treatment period according to the EBMT criteria as assessed by the investigator. The ordering of the responses was: CR, PR, MR, NC and PD. CR was the best response and the poorest response was PD.

Time frame:
every 28 days during treatment period for up to 6 to 8 cycles
Reported as:
Number · participants
Best Reported Disease Response
participantsVAD TreatmentPAD Treatment
CR13
PR64
Response Rate (CR + PR)77
MR23
Overall Response (CR + PR + MR)910
NC53
PD00
Unknown/Unable to Assess10
SecondaryDuration of Response (DOR)

DOR was defined as the duration from the date of the best confirmed response for subjects who achieved CR or PR to the date of first documented evidence of PD (or relapse for subjects who experienced CR) over the duration of the study. DOR = (\[Date of PD or date of censoring - Date of best response\]+1)/30.44.

Time frame:
every 28 days during treatment period for up to 6 to 8 cycles
Reported as:
Number · months
Duration of Response (DOR)
monthsVAD TreatmentPAD Treatment
patient 11.68 (1.68 to 6.18)2.83 (2.83 to 7.69)
patient 26.187.69
patient 33.715.52
patient 45.426.57
patient 54.734.96
patient 6NA7.42

Adverse events

Collected over For up to 6 to 8 cycles, consisting of 28 days each, and for up to a 1-year follow-up period. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VAD Treatment—6/16 (37.5%)15/16 (93.8%)
PAD Treatment—5/13 (38.5%)8/13 (61.5%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventVAD TreatmentPAD Treatment
PneumoniaInfections and infestations2/161/13
Angina unstableCardiac disorders0/161/13
AstheniaGeneral disorders0/161/13
Bursitis infectiveInfections and infestations0/161/13
Cardiac failure chronicCardiac disorders0/161/13
CoughRespiratory, thoracic and mediastinal disorders0/161/13
DiarrhoeaGastrointestinal disorders0/161/13
NeutropeniaBlood and lymphatic system disorders1/161/13
Pyelonephritis acuteInfections and infestations0/161/13
Respiratory failureRespiratory, thoracic and mediastinal disorders0/161/13
Most frequent other events
Showing 10 of 47
Most frequent other events
EventVAD TreatmentPAD Treatment
InsomniaPsychiatric disorders2/164/13
LymphopeniaBlood and lymphatic system disorders4/162/13
NeutropeniaBlood and lymphatic system disorders4/161/13
FatigueGeneral disorders3/162/13
HypertensionVascular disorders1/162/13
Peripheral sensory neuropathyNervous system disorders1/162/13
Back painMusculoskeletal and connective tissue disorders2/161/13
Bronchitis acuteInfections and infestations2/161/13
DiarrhoeaGastrointestinal disorders2/161/13
LeukopeniaBlood and lymphatic system disorders2/160/13

Baseline characteristics

Age, Continuous
Age, Continuous(years)VAD TreatmentPAD TreatmentTotal
Mean64.0 ± 9.461.5 ± 11.362.9 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)VAD TreatmentPAD TreatmentTotal
Female538
Male111021
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VAD TreatmentPAD TreatmentTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White161329
More than one race000
Unknown or Not Reported000
Karnofsky Performance Status
Karnofsky Performance Status(participants)VAD TreatmentPAD TreatmentTotal
≤50000
60112
70134
809312
90538
100033
Body Surface Area
Body Surface Area(m2)VAD TreatmentPAD TreatmentTotal
Mean1.855 ± 0.2331.924 ± 0.2191.886 ± 0.226
Height
Height(cm)VAD TreatmentPAD TreatmentTotal
Mean168.8 ± 11.2169.8 ± 9.5169.3 ± 10.3
Weight
Weight(kg)VAD TreatmentPAD TreatmentTotal
Mean75.9 ± 15.778.3 ± 14.577.0 ± 15.0
08

Study locations

16 sites
  • Zagreb, Croatia
  • Leer, Germany
  • Velbert, Germany
  • Debrecen, Hungary
  • Kaunas, Lithuania
  • Klaipeda, Lithuania
  • Vilnius, Lithuania
  • Bialystok, Poland
  • Gdansk, Poland
  • Poznan, Poland
  • Moscow, Russian Federation
  • Samara, Russian Federation
  • St Petersburg, Russian Federation
  • Ankara, Turkey
  • Bursa, Turkey
  • Eskisehir, Turkey
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 6 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2007
First posted
Feb 28, 2007
Start
Dec 2006
Primary completionActual
Jan 2008
CompletionActual
Jan 2008
Results first posted
Mar 21, 2014
Last update
Mar 21, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00441168
Responsible party
Sponsor
First posted
Feb 28, 2007
Start date
Dec 2006
Primary completion
Jan 2008
Completion
Jan 2008
Results posted
Mar 21, 2014
Last update
Mar 21, 2014

Study contacts

Janssen-Cilag International NV Clinical Trial
study director · Janssen-Cilag International NV

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bortezomib

Start the discussion